Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
Explore this paper's citation graph
Summary
The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
- Type
- review
- Published
- 2005-05-14
- Cited by
- 7,406
- References
- 21
- OpenAlex
- https://openalex.org/W1961026612
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:7427749
Keywords
Medicine, Epirubicin, Breast cancer, Tamoxifen, Oncology
References
- Tamoxifen for early breast cancer: an overview of the randomised trials
- UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years.
- Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women.
- The Effects of Estrogen and Selective Estrogen Receptor Modulators on Cardiovascular Risk Factors
- Oxford Textbook of Medicine, 4th Edn
- Adjuvant Chemotherapy in Early Breast Cancer: Optimal and Suboptimal Anthracycline-Containing Regimens
- Letter: Multiple myeloma and renal impairment.
- Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
- Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999.
- Tamoxifen for early breast cancer: better late than never.
- Ovarian ablation in early breast cancer: Overview of the randomised trials
- Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials
- Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials
- Review of mortality results in randomised trials in early breast cancer.
- Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women
- Systemic treatment of early breast-cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths among 75000 women: 1
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Cited by
- Characterization of G protein-coupled estrogen receptor (GPER) in breast epithelial proliferation and morphogenesis
- Tumor dormancy and metastasis.
- Therapie des Mammakarzinoms
- Therapeutic options in the management of metastatic breast cancer.
- Investigations after adjuvant therapy.
- Description and Pre-clinical Validation of Dynamic Molecular Determinants of Sensitivity to Aromatase Inhibitors in Breast Cancer
- Contraception après cancer: balance bénéfice/risque pour une contraception adaptée et acceptée
- Aromatase Inhibitors in Early Hormone Receptor-Positive Breast Cancer
- Chemosensitivity in Breast Cancer
- Adjuvant chemotherapy for early breast cancer: optimal use of epirubicin.
- Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program.
- Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b.
- Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.
- Lymph Node Ratio is More Valuable than Level III Involvement for Prediction of Outcome in Node-Positive Breast Carcinoma Patients
- Breast cancer in elderly women: a different reality? Results from the NORA study.
- Stadienadaptierte Therapie des Mammakarzinoms
- Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation
- DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients--Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and
- Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin
- Colonoscopy capacity in selected New South Wales hospitals
Related papers
- [Acute pulmonary edema during general anesthesia in a young woman treated with epirubicin].
- P5-13-20: TOP2A Amplification Have Associated with Response to Anthracycline-Based Preoperative Chemotherapy in Primary Breast Cancer.
- 5-Fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma
- Prospective Randomized Controlled Study of Cardiopretective Effect of Dexrazoxane on the Female Breast Cancer Patients with Postoperative Chemotherapy
- Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin
- Epirubicin versus doxorubicin: which is the anthracycline of choice for the treatment of breast cancer?
- Epirubicin: is it like doxorubicin in breast cancer? A clinical review.
- New anthracycline analogs in advanced breast cancer.
- The use of dexrazoxane as a cardioprotectant in patients receiving epirubicin-based chemotherapy for metastatic breast cancer
- Comparisons of Cardiotoxicity and Efficacy of Anthracycline-Based Therapies in Breast Cancer: A Network Meta-Analysis of Randomized Clinical Trials